Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)

NCT00038597 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Myelogenous Leukemia, Chronic

Interventions

DRUG: SCH66336

Sponsor

M.D. Anderson Cancer Center